Advertisement
U.S. markets close in 4 hours 5 minutes

Tiziana Life Sciences Ltd (0RP.BE)

Berlin - Berlin Delayed Price. Currency in EUR
0.4660-0.0100 (-2.10%)
As of 04:58PM CET. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4760
Open0.4700
Bid0.4460 x N/A
Ask0.4780 x N/A
Day's Range0.4660 - 0.4760
52 Week Range0.4660 - 1.2100
Volume4,000
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 0RP.BE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Zacks Small Cap Research

      TLSA: First Phase II SPMS Patient Dosed

      By John Vandermosten, CFA NASDAQ:TLSA Tiziana Life Sciences PLC (NASDAQ:TLSA) has achieved a significant milestone dosing its first patient in its Phase IIa study comparing two doses of intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis (na-SPMS). The company also recently dosed four new patients in its expanded access (EA) multiple sclerosis

    • GlobeNewswire

      Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

      NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA) patients. These patients have shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale (MFIS). PET scan findings showing a reduction in mi

    • GlobeNewswire

      Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024

      NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at Biotech Showcase, San Francisco, January 8-10, 2024. The presentation will be primarily focused on the recent commencement of the phase 2 trial with intranasal foralumab, a fully human anti-CD